FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or its fragment against IL-5; to a pharmaceutical composition for the treatment of a disease associated with human IL-5; to an isolated nucleic acid molecule encoding a monoclonal antibody or its antigen-binding fragment against IL-5; to a recombinant expression vector containing the above-mentioned nucleic acid molecule; to an expressing host cell transformed by the above-mentioned vector; to a method for the production of a monoclonal antibody or its antigen-binding fragment against IL-5; to a method and means for the detection or determination of human IL-5; to a method for the treatment of a disease associated with human IL-5; as well as to the use of the above-mentioned antibody or its antigen-binding fragment, a pharmaceutical composition, an isolated nucleic acid molecule, or a combination thereof in the production of a drug for the prevention or treatment of a disease associated with human IL-5.
EFFECT: obtaining an antibody against IL-5.
20 cl, 5 dwg, 19 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
HUMAN INTERLEUKIN-2 VARIANT OR ITS DERIVATIVE | 2019 |
|
RU2799437C2 |
Authors
Dates
2022-05-24—Published
2018-09-28—Filed